Epstein-Barr virus (EBV) has the capacity to immortalize a subpopulation of resting B lymphocytes. Lymphoblastoid cell lines (LCL) established in this way carry the latent EBV genome as multiple copies of an extrachromasomal episome. Viral gene expression in LCLs is highly restricted; products identified correspond to a membrane protein (latent membrane protein; LMP), a nuclear antigen complex (Epstein-Barr nuclear antigens; EBNAs 1 to 6), two small RNA species (EBERs 1 and 2) and RNA species thought to encode a second membrane-associated polypeptide designated terminal protein (TP). Here we have investigated the temporal sequence of expression of the characterized ‘latent’ proteins during the initiation of immortalization when resting B cells are stimulated to enter and traverse the cell cycle. The analysis has been carried out on prolymphocytic leukaemia cells infected in vitro with either the immortalizing B95-8 strain of virus or the non-immortalizing P3HR1 strain. The results reveal that following B95-8 infection, a sequence of EBV expression is initiated within approximately 8 h with the synthesis of detectable levels of EBNA 2 shortly followed by EBNAs 1, 3, 4, 5 and 6. There is then a delay of approximately 40 h until the expression of LMP completes the latent pattern of proteins found in LCLs. P3HR1 infection, however, produces only transient expression of some EBNA species in a small percentage of cells after approximately 48 h. These observations suggest the failure of P3HR1 virus to immortalize may not be due solely to the absence of EBNA 2 expression and that cellular and/or virus-mediated events occur after EBNA synthesis which then facilitate efficient LMP expression and immortalization.
AlldayM. J.,
CrawfordD. H.,
GriffinB. E.1988; Prediction and demonstration of a novel Epstein-Barr virus nuclear antigen. Nucleic Acids Research 16:4353–4367
DambaughT.,
WangF.,
HennessyK.,
WoodlandE.,
RickinsonA.,
KieffE.1986; Expression of Epstein-Barr virus nuclear protein 2 in rodent cells. Journal of Virology 59:453–462
FinkeJ.,
RoweM.,
KallinB.,
ErnbergI.,
RosenA.,
DillnerJ.,
KleinG.1987; Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA 5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. Journal of Virology 61:3870–3878
GordonI.,
WalkerL.,
GuyG.,
BrownG.,
RoweM.,
RickinsonA.1986; Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology 58:591–595
HinumaY.,
KonnM.,
YamaguchiJ.,
WudarskiD. J.,
BlakesleeJ. R.,
GraceJ. T.1967; Immunofluorescence and herpes-type virus particles in the P3HR1 Burkitt lymphoma cell line. Journal of Virology 1:1045–1051
HurleyE. A.,
Thorley-LawsonD. A.1988; B cell activation and the establishment of Epstein-Barr virus latency. Journal of Experimental Medicine 168:2059–2075
KallinB.,
DillnerJ.,
ErnbergI.,
Ehlin-henrikssonB.,
RosenA.,
HenleW.,
KleinG.1986; Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proceedings of the National Academy of SciencesU.S.A 83:1499–1503
KleinG.,
SvedmyrE.,
JondalM.,
PressonP. O.1976; EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. International Journal of Cancer 17:21–26
KleinG.,
GiovanellaB.,
WestmanA.,
StehlinJ. S.,
MumfordD.1975; An EBV-genome negative cell line established from an American Burkitt lymphoma; receptor characteristics, EBV-infectibility and permanent conversion into EBV positive sublines by in vitro infection. Intervirology 5:319–334
LauxG.,
PbrricaudetM.,
FarrellP. J.1988; A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear genome. EMBO Journal 7:769–774
LernerM. R.,
AndrewsN. C.,
MillerG.,
SteitzJ. A.1981; Two small RNAs encoded by Epstein–Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proceedings of the National Academy of SciencesU.S.A 78:805–809
LindahlT.,
AdamsA.,
BjursellG.,
BornkammG.,
Kaschka-DierichC,
JehnU.1976; Covalently closed circular duplex DNA of EBV in a human lymphoid cell line. Journal of Molecular Biology 102:511–530
MannK. P.,
StauntonD.,
Thorley-LawsonD. A.1985; Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. Journal of Virology 55:710–720
MelchersF.,
LernhardtW.1985; Three restriction points in the cell cycle of activated murine B lymphocytes. Proceedings of the National Academy of SciencesU.S.A 83:805–809
MeloJ. V.,
Brito-BabapalleV.,
ForoniL.,
RobinsonD. S. F.,
LuzattoL.,
CatovskyD.1986; Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. International Journal of Cancer 38:531–538
MillerG.,
ShopeT.,
LiscoH.,
StittD.,
LipmanM.1982; Epstein-Barr virus: transformation, cytopathic changes and viral antigens in squirrel monkey and marmoset leucocytes. Proceedings of the National Academy of SciencesU.S.A 69:385–387
MillerG.,
RobinsonJ.,
HestonL.,
LipmanM.1974; Differences between laboratory strains of Epstein–Barr virus based on immortalization, abortive infection and interference. Proceedings of the National Academy of SciencesU.S.A 71:4006–4010
MurrayR. J.,
YoungL. S.,
CalenderA.,
GregoryC. D.,
RoweM.,
LenoirG. M.,
RickinsonA. B.1988b; Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95-8) or non-transforming (P3HR1)virus strains. Journal of Virology 62:894–901
NemerowG. R.,
SiawM. F. G.,
CooperN. R.1986; Purification of the Epstein-Barr virus/C3d complement receptor of human B-lymphocytes: antigenic and functional properties of the purified protein. Journal of Virology 58:709–712
RabsonM.,
GradovilleL.,
HestonL.,
MillerG.1982; Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. Journal of Virology 44:834–844
ReedmanB. M.,
KleinG.1973; Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. International Journal of Cancer 11:499–520
RoweM.,
EvansH. S.,
YoungL. S.,
HennessyK.,
KieffE.,
RickinsonA. B.1987; Monoclonal antibodies to the latent membrane protein Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology 68:1575–1586
SwendemanS.,
Thorley-LawsonD. A.1987; The activation antigen Blast-2, when shed is an autocrine BCGF for normal and transformed B-cells. EMBO Journal 6:1637–1642
TeoC. G.,
GriffinB. E.1987; Epstein-Barr virus genomes in lymphoid cells: activation in mitosis and chromosomal location. Proceedings of the National Academy of SciencesU.S.A 84:8473–8477
Thorley-LawsonD. A.,
NadlerL. M.,
BahnA. K.,
SchooleyR. T.1985; Blast 2 (EBVCS), an early cell surface marker of human B cell activation is superinduced by EBV. Journal of Immunology 134:3007–3012
WallsE. V.,
DoyleM. G.,
PatelK. K.,
AlldayM. J.,
CatovskyD.,
CrawfordD. H.1989; Activation and immortalization of leukemic B cells by Epstein-Barr virus. International Journal of Cancer (in press)
WangF.,
GregoryC. D.,
RoweM.,
RickinsonA. B.,
WangD.,
BirkenbachM.,
KukutaniH.,
KishimotoT.,
KieffE.1987; Epstein-Barr virus nuclear antigen 2 specifically induces expression of B cell activation antigen CD23. Proceedings of the National Academy of SciencesU.S.A 84:3452–3456